Ramucirumab versus placebo in combination with second-line...

The Lancet Oncology 2015 / 05 Vol. 16; Iss. 5

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Tabernero, Josep, Yoshino, Takayuki, Cohn, Allen Lee, Obermannova, Radka, Bodoky, Gyorgy, Garcia-Carbonero, Rocio, Ciuleanu, Tudor-Eliade, Portnoy, David C, Van Cutsem, Eric, Grothey, Axel, Prausová,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
16
Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(15)70127-0
Date:
May, 2015
File:
PDF, 497 KB
english, 2015
Conversion to is in progress
Conversion to is failed